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a  b  s  t  r  a  c  t
Two separate  randomised,  blinded,  multicentre  ﬁeld  trials  were  conducted  to evaluate  the
efﬁcacy  and  safety  of  a combination  of spinosad  and milbemycin  oxime  (MO)  (Trifexis®,
Elanco  Animal  Health)  in the  treatment  and  prevention  of naturally  acquired  ﬂea infes-
tations  and  intestinal  nematode  infections  in  European  dogs.  Treatments  using  Trifexis®
and  each  control  veterinary  product  (CVP)  were  administered  once  on  Day  0 in  both  ﬁeld
studies.
In the ﬂea  ﬁeld  trial, 11  veterinary  clinics  in  France  participated  in the  study.  On  Day  0,
whole  body  ﬂea  comb  counts  were  conducted  on all dogs  being  evaluated  for enrolment.
Dogs  with ≥7 ﬂeas  on Day  0 were  enrolled,  treated  once  on  Day 0 with  spinosad/MO  or the
CVP (Stronghold®;  selamectin)  and  then  underwent  post-treatment  ﬂea counts  on Days  14
and  30.  There  were  150  spinosad/MO  treated  dogs  and  71 CVP  treated  dogs  included  in  the
ﬂea  effectiveness  population.  Effectiveness  against  ﬂeas  (% reduction  in geometric  means;
GM) was  98.97%  and  97.37%  for the  spinosad/MO  treated  dogs,  and  97.43%  and  93.96%  for
the CVP dogs  on  Days  14  and  30,  respectively,  compared  to the  pre-treatment  baseline  ﬂea
counts. Of  the spinosad/MO  dogs,  89.3%  and  80.0%  had  no  live  ﬂeas  on  Days  14 and  30,
compared  to  77.5%  and  70.4%  of the CVP  dogs,  respectively.
In  the nematode  ﬁeld  trial,  data  from  10 veterinary  clinics  in France  and  19  in Ireland
were  pooled.  Faecal  samples  from  dogs  at  each  clinic  were  analysed.  A  positive  result  at
screening  (parasite  eggs  from  Toxocara  canis, Toxascaris  leonina,  Trichuris  vulpis  or Ancy-
lostoma  caninum)  allowed  for enrolment.  Dogs  were  randomised  to  spinosad/MO  or the
CVP (Milbemax®;  MO/praziquantel).  On  Day  8, a post-treatment  faecal  sample  was  taken
and analysed.  Of  2333  dogs  screened  for nematode  eggs,  238  dogs  were  positive  with  one
or more  of  these  nematodes,  and  229  were  enrolled  in  the study.  Of the 229  dogs,  151
were  treated  with  a single  dose  of  spinosad/MO,  and  77 were  treated  with  a single dose
of CVP.  Post-treatment  effectiveness  against  all  nematodes  (% reduction  GM)  was achieved
with reductions  of  98.57%  and  97.57%  for  the  spinosad/MO  treated  dogs  and  CVP dogs,
respectively,  as compared  to  the  pre-treatment  baseline  faecal  egg  counts.
Trifexis® was  shown  to
as  mixed  and  single  intes
administered  as  a single  o
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304-4017/© 2014 Elsevier B.V. All rights reserved. be safe  and  effective  against  natural  infestations  of  ﬂeas  as  well
tinal  nematode  infections  in client  owned  dogs  in Europe  when
ral  administration  at the  recommended  dose.
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1. Introduction
The dog and cat ﬂea species (Ctenocephalides canis and
Ctenocephalides felis) are considered the most important
insect ectoparasites of companion animals worldwide and
may  readily infest humans (Halos et al., 2014). Several stud-
ies have highlighted the high rate of ﬂea infestations that
are common in companion animals, varying between 12%
and 47% in some European countries (Halos et al., 2014)
and most of these documented infestations are with the
predominant ﬂea species of dogs and cats, C. felis. Infec-
tions with intestinal nematodes are also common in dogs
from all parts of the world, including Europe (Grandemange
et al., 2007; Little et al., 2009; Neves et al., 2014; Riggio
et al., 2013). The nematodes, Ancylostoma caninum and
Toxocara canis, are considered two of the most impor-
tant intestinal helminth parasites of dogs with infections
reported from all parts of the world (Bowman et al., 2010;
Schnieder et al., 2011). Infected dogs can play an important
role in the transmission of these two zoonotic nematodes
by excreting eggs directly into the human environment.
The veterinary and public health aspects of hookworm
and Toxocara spp. infections in dogs are well established
(Bowman et al., 2010; Lee et al., 2010; Overgaauw and van
Knapen, 2013). In Europe, there are two hookworm species
routinely found in dogs, A. caninum and Uncinaria steno-
cephala. A. caninum is reported to be found predominantly
in dogs located in central and southern Europe (ESCCAP,
2010).
Anthelmintics or combination products with endectoci-
dal activity with increased spectrum of activity can provide
the pet owner and veterinarian with the ability to treat dogs
that are concurrently infested or infected with multiple
parasite types. The efﬁcacy of a combination of spinosad
and milbemycin oxime (S/MO) in dogs naturally infected
with different species of adult intestinal nematodes has
been previously demonstrated in laboratory dose conﬁr-
mation studies (Schnitzler et al., 2012). More recently it
was shown that a minimum dose of 0.75 mg/kg of MO in
combination with spinosad will prevent the establishment
of the adult stage of the French Heartworm, Angiostrongy-
lus vasorum (Böhm et al., 2014). Thus, the studies described
below were performed in order to assess the safety and
clinical effectiveness of the combination of spinosad and
MO (Trifexis®) under ﬁeld conditions in Europe for the
treatment and prevention of naturally acquired ﬂea infes-
tations and the treatment of intestinal nematode infections
in pet dogs as compared to authorised control veterinary
products (CVP).
2. Materials and methods
2.1. Study design
Two separate randomised, blinded, multicentre ﬁeld tri-
als were conducted. The dogs enrolled in each ﬁeld study
represented a number of climatic regions as well as a
mixture of genders, ages, weights, and dog breeds. The
ﬂea clinical study was conducted from April to July 2011
and was a multi-site clinical study in single- and multi-
dog (maximum of 4 dogs per household and all receivedology 207 (2015) 99–106
the same treatment) households located predominantly in
suburban areas under ﬁeld conditions in France, in two  geo-
graphical distinct areas, central (5 sites) and southern (6
sites) France. In addition a maximum of three cats were
allowed per household. The study involved a blocked ran-
domisation of households to one of two treatment groups.
The order of presentation at the clinic was  used for block-
ing. Eligible dogs at a given site were randomly assigned to
one of two treatment groups in the order of presentation to
the clinic. Each site’s random allocation tables provided for
enrolment in a 2:1 ratio for the SMO  and SEL groups, respec-
tively. Within single-dog households, sets of three dogs
were allocated within each block (two to S/MO and one
to SEL). For multi-dog households each block comprised
3 households, two of which were allocated to S/MO and
one to SEL. Pet owner, sponsor personnel and contract per-
sonnel as well as the treatment technician were unmasked
to the treatment; the investigator (and/or personnel per-
forming the whole body ﬂea comb counts) were masked to
the treatment. The live phase of the study had a duration
of approximately 30 days. All dogs within one household
were treated with the same product, either S/MO or SEL, but
only dogs with ﬂea counts ≥7 ﬂeas on the ﬁrst visit were
included in the subsequent counts on Days 14 and 30. If
cats were present in an enrolled household, they also were
treated with SEL irrespective of the treatment assigned to
the dog(s). During the course of the study three visits were
performed: visit 1: dog enrolment and ﬁrst dosing (in the
clinic or at home) on Day 0; visit 2 on Day 14 and visit
3 on Day 30. On all of these visits, physical examinations
and whole body ﬂea comb counts were performed and the
dogs were also weighed during visits 1 and 3. In addition,
owner observations and conﬁrmation of dosing were col-
lected within 3 days of visit 1 via telephone contact with
the clinic.
The nematode clinical study was a positive controlled
randomised study with a parallel group design con-
ducted with cases recruited from 10 investigational centres
(located predominantly in suburban veterinary clinics)
in France and 19 in Ireland. Data from both countries
were pooled. Dogs were randomised to either the S/MO
(Trifexis®) or a (Milbemax; MO in combination with praz-
iquantel; MO/P) group. The randomisation was speciﬁc to
the site and was unique for single-, and multi-dog house-
holds. All nematode positive dogs in the same household
received the same treatment. Only those dogs with a pos-
itive faecal egg count and which met  all of the inclusion
criteria and for which none of the exclusion criteria applied
were allocated to treatment. These dogs were blocked by
consecutive order of enrolment in the study. Each site’s
random allocation tables provided for enrolment in a 2:1
ratio for the S/MO and MO/P groups, respectively. Within
single dog households, sets of three dogs with positive fae-
cal egg counts were allocated within each block (two to
S/MO and one to MO/P). For multi-dog households, when
more than one dog within a household was positive for
faecal eggs at screening, all positive dogs in the household
received the same treatment. This was  to mitigate the risk
of treatment with the wrong product. Dogs from multi-
dog households had to be dosed on the same Day 0 with
the same treatment. For multi-dog households with more
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han one positive dog, each block comprised 3 households,
wo of which were allocated to S/MO and one to MO/P. If
he household consisted of multiple dogs but only one was
ositive for faecal eggs at screening, the dog was  allocated
er the single-dog household list. A single reference labo-
atory was selected (Charles River Laboratories, Ireland) to
arry out all faecal examinations for inclusion of dogs into
he study and for examinations performed post-treatment.
nitial screening faecal samples were assessed primarily to
onﬁrm the presence of T. canis, Toxascaris leonina, Trichuris
ulpis,  A. caninum and U. stenocephala. A positive result at
creening (i.e. >0 parasite eggs from T. canis, T. leonina,  T.
ulpis or A. caninum identiﬁed) enabled the dog to proceed
o Day 0 sampling and dosing.
Both studies were conducted in compliance with the
ommittee for Veterinary Medicinal Products European
nion Note for Guidance “Good Clinical Practice for Con-
uct of Clinical Trials for Veterinary Medical Products’ (July
001) in order to follow the EMA  CVMP guidelines for the
esting of antiparasitic substances against ticks and ﬂeas.
nformed consent was obtained from the dogs’ owners
efore enrolment.
.2. Selection of animals
In both ﬁeld studies, client owned dogs of any breed
nd sex, aged more than 2 months and suspected to have
 natural ﬂea infestation and/or an intestinal nematode
nfection were examined and if they met  all relevant inclu-
ion criteria, were selected for enrolment. The primary
xclusion criteria included dogs less than 8 weeks of age;
ogs <2.0 kg body weight; dogs enrolled in another clin-
cal study; pregnant or nursing bitches, or bitches that
ere intended for breeding use within 2 months of enrol-
ent; unweaned puppies; dogs that had travelled outside
f the EU in the last year; dogs that had been treated
ith any ﬂea control product with ongoing residual efﬁ-
acy as per label; dogs treated with drugs active against
astrointestinal nematodes in the preceding 3 months;
ogs with pre-existing medical and/or surgical conditions
hat would impact the collected study data; and dogs that
ere owned by the investigator, one of the participating
ospitals/clinics veterinarians or staff or a family member
hereof.
.3. Treatments
To assess the clinical effectiveness and safety of S/MO
Trifexis®), enrolled dogs were given a ﬂavoured combi-
ation tablet of spinosad/milbemycin oxime. The S/MO
ablets were administered orally at a dose rate of 45–70 mg
pinosad and 0.75–1.17 mg  MO/kg bodyweight. To ensure
aximum absorption of each drug, S/MO treated dogs
ere instructed to be fed around the time of dosing. The
arketed CVP products selected and used in the ﬂea and
ematode ﬁeld studies were SEL because of its month long
dult ﬂea claim and MO/P because of its broad spectrum
ntestinal nematode efﬁcacy, respectively. Each of these
ontrol products was administered as per label instructions
rom the manufacturer including giving food around the
ime of dosing.ology 207 (2015) 99–106 101
2.4. Efﬁcacy and safety assessment
The effectiveness of the S/MO combination and SEL were
assessed through the reduction in natural ﬂea burdens
based on the Day 14 and Day 30 ﬂea counts as compared
to the baseline pre-treatment infestation level. The ﬂea
counts were log-transformed, statistically modelled and
reductions based on model geometric means (GM) were
compared between the two treatment groups in order to
assess non-inferiority of the S/MO combination as com-
pared to SEL.
In the nematode ﬁeld study, the primary efﬁcacy param-
eter was  the % reduction in GM faecal egg counts (eggs/g;
EPG) between the pre-treatment sample and the post-
treatment sample. This was  performed separately for each
of the four parasites of interest in this study (T. canis, T.
leonina, T. vulpis and A. caninum). A secondary efﬁcacy
parameter was  the reduction in GM U. stenocephala faecal
EPG counts since previous experimentally induced infec-
tions in laboratory dose conﬁrmation studies with the
S/MO combination had not given 90% or above efﬁcacy. The
EPG counts were log-transformed, statistically modelled
and the reductions based on model GM were compared
between the two  treatment groups in order to assess non-
inferiority of the S/MO combination as compared to MO/P.
In the ﬂea ﬁeld study, trained, masked individuals at
each site performed whole body ﬂea comb counts during
the course of the study. One extra-ﬁne-tooth ﬂea comb was
used for each case. Only viable ﬂeas (demonstrating nor-
mal  movement and behaviour) were counted. Dogs were
combed continually for at least 5 min  or until no more ﬂeas
were found for 5 min.
In the nematode ﬁeld study, all faecal samples
(screening, Day 0 and Day 8 samples) were sent via courier
or postal service to a reference testing facility, Charles River
Laboratory in Ireland. Freshly collected faecal samples from
each dog were shipped ambient or chilled with ice packs,
and were stored in a refrigerator prior to shipment and
upon receipt. Nematode infections were assessed at the
reference laboratory by suitably qualiﬁed personnel, who
were blinded to the allocation of animals to treatment.
Fresh faecal samples for assessment of T. canis, T. leonina,  T.
vulpis, or A. caninum (and U. stenocephala, if present) infec-
tions were taken from dogs 7 to 14 days prior to Day 0
(screening), on Day 0 prior to treatment (to conﬁrm ongo-
ing infections) and again on Day 8. All EPG counts were
carried out by the reference laboratory using the same
methods. For the screening faecal examination, the McMas-
ter method was  used. Brieﬂy, 4 g of faeces were suspended
in 56 mL of a sugar ﬂotation solution (sp. Grav. > 1.2) and
processed and examined as per the McMaster technique
(Zajac and Conboy, 2006). For the Day 0 prior to treat-
ment and the Day 8 post-treatment faecal examinations,
a direct faecal double centrifugation ﬂotation method was
used. Brieﬂy, 1–2 g ± 0.1 g of fresh faeces were weighed
and mixed with 20 ± 1 mL  water and thoroughly mixed
and processed using published methods (Zajac and Conboy,
2006). During the examination of each faecal sample, the
number of eggs counted for each of the ﬁve nematode
species of interest was  divided by the number of grams of
faeces weighed out and used to determine the EPG of each
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nematode species for each individual dog. Differentiation
of hookworm eggs was based on the size of the eggs and the
experience of the parasitologist at the reference laboratory.
The safety of S/MO combination in each ﬁeld study was
evaluated through review of adverse events and changes
in body weight during the study.
2.5. Statistical analysis
These data were skewed in both studies irrespective
of treatment group, particularly at the pre-treatment time
point; therefore, log transforming the counts for analysis
was appropriate. The use of GM was appropriate in highly
skewed data distributions to estimate the centre of the data
distribution and permit valid statistical analysis.
Flea count data were log-transformed and analysed
using repeated measures mixed model methodology. The
correlation between observations on the same dog and
between dogs within the same household was accounted
for in the model.
The reduction in ﬂea count was calculated using back-
transformed model LS means with the following equation:
%Reduction =
(
Geometric meanpre-treatment − Geometric 
Geometric meanpre-treatme
Non-inferiority of the S/MO group in relation to SEL
was declared if both products were effective as deﬁned by
statistically signiﬁcant reduction of the ﬂea infestation by
≥90%.
The treatment difference and corresponding 95% con-
ﬁdence interval in the proportion of dogs successfully
treated was calculated. Success in an individual dog was
deﬁned as a reduction of at least 90% in ﬂea count post-
treatment compared to the pre-treatment count.
The primary efﬁcacy parameter in the nematode study
was the % reduction in GM faecal egg counts between the
pre-treatment sample and the post-treatment sample. This
was performed separately for each of the four parasites of
interest in this study (T. canis, T. leonina, T. vulpis and A. can-
inum). Secondary efﬁcacy parameters were the reduction
in GM U. stenocephala faecal EPG counts and the reduction
in total infection (total infection was deﬁned as the sum of
the egg counts from all 5 species enumerated.)
For each of the primary and secondary efﬁcacy variables
the faecal egg count data were analysed using repeated
measures mixed models, accounting for the correlation
between observations on the same dog and between dogs
within the same household. The same criteria were used to
assess non-inferiority and calculate success rates as in the
ﬂea count data assessment.
The reduction in egg count was calculated using the
following equation:
%Reduction =
(
Geometric meanpre-treatment − Geometric 
Geometric meanpre-treatmeData from small individual study sites (<4 households
with efﬁcacy evaluable cases) were pooled for analysis
within geographical region. In instances where, after initial
pooling within region (i.e. central versus southern France)ology 207 (2015) 99–106
ost-treatment
)
× 100.
ost-treatment
)
× 100
there remained sites with <4 households with efﬁcacy
evaluable data, pooling also occurred across regions.
For each of the primary and secondary variables, the
proportion of dogs successfully treated was  also calculated;
success in an individual dog was deﬁned as a reduction of
at least 90% in faecal egg count post-treatment compared
to the pre-treatment count.
3. Results
Eleven veterinary clinics situated in geographically
diverse regions of France participated in the ﬂea study.
54.5% of S/MO cases and 53.4% of SEL cases were located
in central France and the remainder in southern France.
In total, 176 S/MO treated dogs and 88 SEL treated dogs
remained on study through to the ﬁnal visit at Day 30. A
total of 150 S/MO treated dogs and 71 SEL treated dogs
were included in the effectiveness evaluable population.
Ten sites contributed data to the effectiveness evaluable
population; One site (site 10) was  excluded as it had <4
households and although eligible for pooling, there were
no other sites in the region to pool this site with. Site 7
included the largest number of cases in the effectiveness
evaluable population (28 S/MO and 13 SEL cases).
The primary objective of the study was  to demonstrate
non-inferiority of S/MO in combination when compared to
SEL. During the course of this study, the S/MO treated dogs
demonstrated >95% reductions at both post-baseline ﬂea
count assessments based on geometric means (Table 1).
Non-inferiority between treatments was demonstrated.
The success rates for S/MO were 96.7% and 88.7%, on Days
14 and 30, respectively, compared with 85.9%, and 73.2%
for the SEL.
The number of dogs (percent) with no live ﬂeas in the
S/MO-treated group at Days 14 and 30 were 89.3% and
80.0%, respectively (Table 2). The number of dogs (percent)
with no live ﬂeas in the SEL group at Days 14 and 30 were
77.5% and 70.4%, respectively.
Prior to treatment on Day 0 the GM number of ﬂeas
combed from the 150 effectiveness evaluable dogs in the
S/MO group was  16.4 (range 7–175). In the SEL group the
GM was 12.0 (range 7–47) (Table 1). By Day 14 the GM
ﬂea counts were signiﬁcantly (p < 0.001) reduced in both
groups to 0.2 in the S/MO group and 0.3 in the SEL group
(Table 1). In the S/MO group the reduction was  98.97% andfor SEL the corresponding reduction was 97.43%. The
level of reduction in ﬂea burden remained signiﬁcant
(p < 0.001) in both groups at Day 30. In the S/MO group the
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Table  1
Geometric mean ﬂea counts and percent reductions (as compared to baseline) in IVP and CVP treatment groups.
Effectiveness Baseline geometric mean ﬂea count (range) Geometric mean ﬂea count (% reduction)
Day 14 Day 30
Spinosad/MO (IVP) 16.4 (7–175) 
Selamectin (CVP) 12.0 (7–47) 
Table 2
Percentage of f dogs with no live ﬂeas in the IVP and CVP treated groups
at  Days 14 and 30 post-treatment.
Percent dogs with no live ﬂeas
Day 14 Day 30
Spinosad/MO (IVP) 89.3 80.0
r
s
o
b
3
ﬂ
i
ﬂ
t
ﬂ
randomised onto the study. Of these 229 dogs, 151 were
T
G
s
fSelamectin (CVP) 77.5 70.4
eduction was 97.37% (GM = 0.4) and for SEL the corre-
ponding reduction was 93.96% (GM = 0.7). Comparison
f the treatment groups showed no signiﬁcant difference
etween the treatments at either Day 14 (p = 0.180) or Day
0 (p = 0.148). Success rates, deﬁned as ≥90% reduction in
ea count compared to pre-treatment for an individual dog
n the S/MO group was 96.7% with 89.3% of dogs with no live
eas. This compares favourably with the SEL group where
he success rate was 85.9% with 77.5% of dogs with no live
eas. The mean difference in success rates at Day 14 was
able 3
eometric mean (GM), percentage reduction and p-value of faecal egg count
pinosad/milbemycin oxime or a control veterinary product (CVP).
Nematode type Baseline pre-treatment GM faecal EPG coun
Spinosad/MO CVP 
Toxocara canis
EPG GM 42.0 27.4 
%  Reduction 
p-valuec
Toxascaris leonina
EPG GM 19.0 15.3 
%  Reduction 
p-valuec
Trichuris vulpis
EPG GM 72.5 80.2 
%  Reduction 
p-valuec
Ancylostoma caninum
EPG GM 67.0 92.3 
%  Reduction 
p-valuec
Uncinaria stenocephala
EPG GM 44.2 25.1 
%  Reduction 
p-valuec
All  nematodes
EPG GM 94.0 93.9 
%  Reduction 
p-valuec
a Geometric mean = exp (LS mean) − 1, which used LS mean values from the mi
b Percent reduction in geometric mean = 100 × ((geometric mean for Day 0 vis
or  Day 0 visit 1).
c p-value for the difference between pre- and post-treatment faecal egg count 0.2 (98.97) 0.4 (97.37)
0.3 (97.43) 0.7 (93.96)
11% and was  signiﬁcant based on the 95% conﬁdence inter-
val for the difference (2–19%). At Day 30 the success rate
in the S/MO group was 88.7% with 80.0% of dogs with no
live ﬂeas and the success rate in the SEL group was  73.2%
(70.4% with no live ﬂeas). The difference in success rates
at Day 30 was  also signiﬁcant based on the 95% conﬁdence
interval (4–27%).
In total 10 adverse events (AEs) were observed in seven
S/MO treated dogs in the ﬂea ﬁeld study. Overall, the high-
est frequency AE was  emesis during the course of the study
(animal rate 2.2%, incidence 2.2%) and starting on the day
of or day following dosing with 3 events in the S/MO group.
In the SEL group there were two AEs, both in the same dog.
Of the 2333 dogs screened for T. canis, T. leonina,  T.
vulpis and A. caninum eggs in the nematode ﬁeld study,
238 dogs were found to be positive, with 229 subsequentlytreated with a single dose of S/MO, and 77 were treated
with a single dose of MO/P. The nematode species present
on Day 0 were well balanced between the two  treatment
s (EPG) of nematode parasites in dogs treated with a combination of
ts Post-treatment GM faecal EPG countsa,b
Spinosad/MO CVP
0.4 0.9
99.06% (N = 53) 96.68% (N = 26)
<0.001 <0.001
0.0 0.6
99.5% (N = 5) 96.39% (N = 2)
0.008 0.085
0.9 1.0
98.79% (N = 70) 98.76% (N = 39)
<0.001 <0.001
0.0 0.3
99.98% (N = 45) 99.65% (N = 22)
<0.001 <0.001
3.2 5.0
92.8% (N = 35) 79.9% (N = 23)
<0.001 <0.001
1.3 2.3
98.57% (N = 134) 97.57% (N = 73)
<0.001 <0.001
xed model analysis, where LS mean = least squares mean.
it 1 − geometric mean for post-treatment Day 8 visit 2)/geometric mean
within treatment group.
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Table  4
Success rates of post-treatment faecal egg count reduction by type of nematode and for all nematodes.
Nematode type Treatment Successa Comparison Difference in
success ratesb (%)
95%CIc
T. canis
Spinosad and MO  (N = 53) 50 (94.3%)
Spinosad/MO – Milbemax 6 8–20Milbemax (N = 26) 23 (88.5%)
T.  leonina
Spinosad and MO  (N = 5) 5 (100.0%)
Spinosad/MO – Milbemax 0 0–0Milbemax (N = 2) 2 (100.0%)
T.  vulpis
Spinosad and MO  (N = 70) 63 (90.0%)
Spinosad/MO – Milbemax 0 −12 to 12Milbemax (N = 39) 35 (89.7%)
A.  caninum
Spinosad and MO  (N = 45) 45 (100.0%)
Spinosad/MO – Milbemax 9 −3 to 21Milbemax (N = 22) 20 (90.9%)
U.  stenocephala
Spinosad and MO  (N = 35) 23 (65.7%)
Spinosad/MO – Milbemax 18 −8 to 44Milbemax (N = 23) 11 (47.8%)
All  nematodes
Spinosad and MO  (N = 134) 116 (86.6%)
Spinosad/MO – Milbemax 7 −4 to 18Milbemax (N = 73) 58 (79.5%)
a Success was  the number of dogs with ≥90% individual percent reduction in faecal egg count. Individual percent reduction was calculated using
100  × ((Day 0 visit 1 pre-treatment faecal egg count − Day 8 visit 2 post-treatment faecal egg count)/Day 0 visit 1 pre-treatment faecal count).
ch treatm
 to the bb Success rate was the proportion of dogs in a treatment group for whi
c 95% conﬁdence interval (CI) was  based on the normal approximation
groups. 56.0% of dogs in the S/MO group had single infec-
tions versus 56.2% in the MO/P group. The remaining
dogs had mixed infections with 2–4 nematode species.
The geographical distribution of cases in the effectiveness
evaluable population shows that 28.4% of the dogs in the
S/MO group and 30.1% of the dogs in the MO/P group
were from Ireland. The remaining 71.6% (S/MO) and 69.9%
(MO/P) of dogs were from France. However, there was  some
variation in the distribution of nematode types. T. canis was
relatively evenly distributed between Ireland and France
with 58.5% (IVP) and 69.2% (S/MO) of T. canis cases from
Ireland. T. leonina was found exclusively in Ireland (n = 7),
T. vulpis was found predominantly in France with 95.7%
(S/MO) and 89.7% (MO/P) of dogs with T. vulpis from France.
U. stenocephala was found in Ireland and France in the ratio
expected for the geographical distribution of cases with
71.4% (S/MO) and 78.3% (MO/P) in France. A. caninum was
found exclusively in France (n = 67).
Percent reductions in post-treatment geometric mean
faecal egg counts were performed separately for each of
the four parasites of primary interest in this study (T. canis,
T. leonina, T. vulpis and A. caninum), and for the secondary
parameters of U. stenocephala and the reduction in total
infection, ‘all nematodes’ (Tables 3 and 4).
For the safety assessment aspect of this nematode ﬁeld
study, 3 from 151 dosed animals in the S/MO group (2.0%)
reported an adverse event (AE), 2 of which were diar-
rhoea and 1 of which was dermatitis/eczema. From the
MO/P group, 2 from 77 dosed animals (2.6%) reported an
AE, both of which were diarrhoea. No AEs started on the
day of or day following dosing and there was no emesis
observed.
4. DiscussionIn both randomised, blinded, CVP controlled multi-
centre European ﬁeld trials, the combination of S/MO for
the treatment of natural ﬂea infestations as well as adult
intestinal nematode infections was highly successful asent was  successful.
inomial distribution.
compared to positive reference CVPs. The cat ﬂea is con-
sidered the most common insect ectoparasite of dogs in
Europe (Halos et al., 2014). In the face of high prevalence of
the cat ﬂea that has both pathogenic and vector potential,
effective integrated adult ﬂea control represents a major
and ongoing objective in small-animal veterinary practices.
In the nematode ﬁeld study, dogs enrolled with positive
faecal egg counts were also found to be infested with ﬂeas
(35.1–38.4% in both treatment groups), so the routine use
of a broad spectrum endectocide like Trifexis® will con-
trol multiple endo- and ectoparasites in dogs when used
by pet owners. A large number of dogs were screened
(N = 2339) to identify dogs positive (N = 238) for nema-
tode eggs; however, these results demonstrate that worm
infections are common (ca. 10% in this study) in dogs in
Europe. This prevalence is similar to what other authors
have found in dog faecal surveys conducted in Europe
(Schnieder et al., 2011). The most commonly found intesti-
nal nematode species seen in this ﬁeld study, either alone
or in combination, including the zoonotic parasites T. canis
and A. caninum, demonstrate the need to routinely con-
duct faecal examinations and to treat client owned dogs
for these different intestinal nematode parasites. In a num-
ber of dogs in this study, Day 0 pre-treatment faecal egg
count numbers were very high, establishing the high risk
of environmental contamination by non-treated, infected
dogs in home environments. The zoonotic potential of T.
canis and A. caninum are well known in the scientiﬁc liter-
ature, including in Europe (Bowman et al., 2010; Deplazes
et al., 2011; Lee et al., 2010; Overgaauw and van Knapen,
2013). Schnieder et al. (2011) summarised the prevalence
of T. canis in several European countries. Human expo-
sure based on seroprevalance to T. canis has also been
reported in different regions of the world where the age
adjusted Toxocara seroprevalence was 13.9% (Won  et al.,
2008; Manini et al., 2012). Macpherson (2013) reviewed
the most common control measures for T. canis, includ-
ing regular and frequent anthelmintic treatment of dogs
starting at an early age, education and enforcement of
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aws for the disposal of canine faeces, dog legislation and
ersonal hygiene. Since T. canis eggs are very environmen-
ally resistant and can survive well over most winters in
emperate climates, reducing environmental contamina-
ion from infected dogs is very important. Additionally, T.
anis can be routinely found in both juvenile and mature
ogs (Fahrion et al., 2008), so routinely monitoring and
reating of all age classes of dogs is important.
The availability of broad spectrum endectocides to pet
wners that effectively treat dogs with adult intestinal
ematodes helps to address recommendations made to
eterinarians (Epe, 2009) and recommendations by expert
roups such as ESCCAP (2010) to routinely treat and control
ll intestinal nematodes. This is of particular importance
or zoonotic species like T. canis and A. caninum that have
een shown to be consistently found in dogs of all ages
nd throughout the year in prevalence studies conducted
n different areas of the world, including healthy, well-
ared for dogs in Europe (Martinez-Moreno et al., 2007;
iggio et al., 2013; Neves et al., 2014). ESCCAP (2010) points
ut that there is surprisingly little information about the
mpact of re-treatment intervals on parasite burdens and
nvironmental contamination on which to base a maxi-
um  re-treatment interval. However current information
uggests annual or twice yearly treatments do not have a
igniﬁcant impact on preventing patent infection within
 population of dogs, so a treatment frequency of at least
 times per year is a general recommendation. ESCCAP
2010) further states that it has been shown that an increase
n treatment frequency effectively reduces the occurrence
f positive animals; studies have shown that deworming
reatments four times a year does not necessarily eliminate
atent infections, while monthly deworming treatments
an largely prevent patent infections as it takes into account
he biology of these intestinal nematode parasites. This
s exempliﬁed in a recent publication that demonstrated
hat the prevalence of common nematode and cestode
ndoparasites has declined signiﬁcantly in a population of
ell-cared for dogs that were analysed and was attributed
o the monthly use of broad spectrum endectocides (Gates
nd Nolan, 2014). The highly signiﬁcant reduction (92.8%)
n U. stenocephala egg counts indicates that the combina-
ion of S/MO is additionally reducing or affecting egg laying
f adult worm populations of this hookworm species, pos-
ibly due to the higher MO minimum dose (0.75 mg/kg) as
ompared to Milbemax, even though there is not a spe-
iﬁc label claim for this parasite on the European Trifexis®
abel.
In conclusion and based on the results presented above
or both ﬁeld studies, the combination of spinosad and
ilbemycin oxime was shown to be a safe and effective
roduct for the treatment and prevention of ﬂeas (C. felis)
nd the treatment of commonly found intestinal nema-
odes of dogs in Europe.
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